- May 23, 2018
- Posted by: PharmaScroll
- Category:
Multiple Sclerosis is an autoimmune disorder in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS.
SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses and remissions. Nearly 50% of RRMS patients progress to SPMS in a 10 year time period. In SPMS, the patients might not have relapses at all but the symptoms may not completely go off (plateau) in the remission period.
As per the current scenario in Multiple Sclerosis indication, there are over 15 molecules approved in the worldwide market. However, majority of the molecules are approved in the Relapsing Remitting form of Multiple Sclerosis. The more progressive forms of Multiple Sclerosis like Secondary Progressive MS and Primary progressive MS are still to encounter the boom in terms of number of launched molecules.
However, as per a recent study published in PLOS one, Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained using minimally invasive procedures.
About the study:
In a triple-blind, placebo-controlled study, cell samples were obtained from consenting patients by lipectomy and subsequently expanded. Patients were randomized to a single infusion of placebo, low-dose(1x106cells/kg) or high-dose(4x106cells/kg) autologous AdMSC product and followed for 12 months. Safety was monitored recording adverse events, laboratory parameters, vital signs and spirometry. Expanded disability status score (EDSS), magnetic-resonance-imaging, and other measures of possible treatment effects were also recorded.
Results of the study:
Thirty-four patients underwent lipectomy for AdMSCs collection, were randomized and thirty were infused (11 placebo, 10 low-dose and 9 high-dose); 4 randomized patients were not infused because of karyotype abnormalities in the cell product. Only one serious adverse event was observed in the treatment arms (urinary infection, considered not related to study treatment). No other safety parameters showed changes. Measures of treatment effect showed an inconclusive trend of efficacy.
The study concluded that the infusion of autologous AdMSCs is safe and feasible in patients with SPMS. The study further highlighted the need for larger studies and probably treatment at earlier phases to investigate the potential therapeutic benefit of the technique.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/
News Source: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195891
Image Source: https://www.verywellhealth.com/secondary-progressive-ms-2440762